AU2023205910A1 - Methods of treating asthma with anti-light antibodies - Google Patents

Methods of treating asthma with anti-light antibodies Download PDF

Info

Publication number
AU2023205910A1
AU2023205910A1 AU2023205910A AU2023205910A AU2023205910A1 AU 2023205910 A1 AU2023205910 A1 AU 2023205910A1 AU 2023205910 A AU2023205910 A AU 2023205910A AU 2023205910 A AU2023205910 A AU 2023205910A AU 2023205910 A1 AU2023205910 A1 AU 2023205910A1
Authority
AU
Australia
Prior art keywords
light
subject
light antibody
antibody
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023205910A
Other languages
English (en)
Inventor
Sheridan J. CARRINGTON
Garry A. NEIL
H. Jeffrey Wilkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avalo Therapeutics Inc
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of AU2023205910A1 publication Critical patent/AU2023205910A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023205910A 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies Pending AU2023205910A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296786P 2022-01-05 2022-01-05
US63/296,786 2022-01-05
US202263396308P 2022-08-09 2022-08-09
US63/396,308 2022-08-09
PCT/US2023/060064 WO2023133389A2 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Publications (1)

Publication Number Publication Date
AU2023205910A1 true AU2023205910A1 (en) 2024-06-06

Family

ID=87074254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023205910A Pending AU2023205910A1 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Country Status (6)

Country Link
US (1) US20250002598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460523A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025501865A (cg-RX-API-DMAC7.html)
AU (1) AU2023205910A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240327A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023133389A2 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484696B1 (en) * 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
HK1257443A1 (zh) * 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法

Also Published As

Publication number Publication date
EP4460523A2 (en) 2024-11-13
US20250002598A1 (en) 2025-01-02
EP4460523A4 (en) 2025-12-17
CA3240327A1 (en) 2023-07-13
WO2023133389A2 (en) 2023-07-13
JP2025501865A (ja) 2025-01-24
WO2023133389A3 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
JP7842268B2 (ja) Il-4r拮抗薬の投与により喘息を処置または予防するための方法
EP2627673B1 (en) Therapies for improving pulmonary function
JP2013544235A5 (cg-RX-API-DMAC7.html)
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
HK40114122A (en) Methods of treating asthma with anti-light antibodies
US12331107B2 (en) Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
JP7343547B2 (ja) Il-4r拮抗薬の投与により喘息を処置または予防するための方法
WO2023121643A1 (en) Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
TW202544036A (zh) 用抗tslp抗體治療慢性阻塞性肺病
WO2026015176A1 (en) Methods of treating hidradenitis suppurativa with anti-il-1beta antibodies
US20240158522A1 (en) Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function